Deputy Chief Physician, Third Ward, Gastrointestinal Oncology Center, Peking University Cancer Hospital. **Specialty:** Minimally invasive surgery and comprehensive treatment for gastric cancer, colon cancer, rectal cancer, gastrointestinal stromal tumors (GIST), and intestinal obstruction. **Professional Affiliations:** Member of the Ostomy Group, Anorectal Surgeons Branch, Chinese Medical Doctor Association; Member of the Committee for Standardized Diagnosis and Treatment of Tumors, China Primary Health Care Foundation; Member of the Colorectal Tumor Committee, Beijing Oncology Society; Member of the Beijing Cancer Prevention and Treatment Society; Selected for the "Young Seedling Talent" Program of the Beijing Hospitals Authority. **Representative Achievements:** Principal Investigator for two intramural research grants from Peking University Cancer Hospital; participated in one project under the "Yangfan" Plan of the Beijing Hospitals Authority and one project under the National Natural Science Foundation of China. **Representative Publications:** 1. Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02) Peng-Ju Chen, Lin Wang, Ting-Ting Sun, Yun-Feng Yao, Yi-Fan Peng, Jun Zhao, Tian-Cheng Zhan, Jia–Hua Leng, Yong Cai, Yong-Heng Li, Xiao-Yan Zhang, Ying-Shi Sun, Zhong-Wu Li, Wei-Hu Wang, Ai-Wen Wu. *Gastroenterology Report*, Volume 11, 2023, goad017, (First Author, IF=4.063) 2. Survival outcomes of stage I colorectal cancer: development and validation of the ACEPLY model using two prospective cohorts. Qingbin Wu#, Pengju Chen#, Chi Shu#, Lin Chen, Zechuan Jin, Jun Huang, Xin Wang, Xue Li, Mingtian Wei, Tinghan Yang, Xiangbing Deng, Aiwen Wu, Yazhou He*& Ziqiang Wang* *BMC Medicine*, 21, 3 (2023). (Co-first Author, IF=11.150) 3. Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer. Lujing Yang#; Pengju Chen#; Li Zhang; Lin Wang; Tingting Sun; Lixin Zhou; Zhongwu Li*; Aiwen Wu* *British Journal of Cancer*, 2020, 123(6). (Co-first Author, IF=7.644) 4. Clinical Decision Support for High-Risk Stage II Colon Cancer: A Real-World study of Treatment Concordance and Survival. Pengju Chen#; Tianle Li#; Ting-ting Sun; Van C. Willis; M. Christopher Roebuck; Dena M. Bravata; Xin-zhi Liu; Yull Edwin Arriaga; Irene Dankwa-Mullan; Ai-wen Wu*. *Diseases of the Colon & Rectum*, 2020, 63(10): 1383-1392. (First Author, IF=4.580) 5. Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study. Chen P#, Yao Y and Gu J. *International Journal of Colorectal Disease* 2015;30:1695-704. (First Author, IF=2.574)